Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Of Bone Cement Complications In Vertebroplasty/Kyphoplasty

This article was originally published in The Gray Sheet

Executive Summary

FDA is formulating regulatory requirements for evaluating the safety and efficacy of bone cement products used in vertebroplasty and kyphoplasty procedures, the agency says in 1an Oct. 31 FDA public health web notification

You may also be interested in...



Spine Compression Fracture Treatments Compared By Cost, Leak Rate

The potential safety advantages of kyphoplasty over vertebroplasty and its ability to stave off additional spine repair procedures may outweigh its higher cost, according to speakers at the HealthPoint SPINE Summit in New York Oct. 9

Spine Compression Fracture Treatments Compared By Cost, Leak Rate

The potential safety advantages of kyphoplasty over vertebroplasty and its ability to stave off additional spine repair procedures may outweigh its higher cost, according to speakers at the HealthPoint SPINE Summit in New York Oct. 9

Regulatory News In Brief

HHS issues conflict of interest draft guidance: "1Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection" recommends taking measures such as separating responsibility for financial and research decisions and establishing CoI committees to verify the absence of financial interests. Aimed at individuals and organizations engaged in human subjects research, the March 31 guidance provides points to consider and aligns with December 2001 GAO recommendations calling on HHS to develop best practices for managing investigator and institutional financial CoI in biomedical research. Comments on the guidance are due by May 30...

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel